Clover SGM

Clover Biopharmaceuticals is a global clinical-stage biotechnology company committed to developing transformative biologics as vaccines and therapeutics for world-threatening diseases. The company's proprietary Trimer-Tag technology platform allows for the production of novel, trimerized fusion proteins that mimic the natural structure of viral and tumor-associated proteins. Clover's lead product, SCB-2019, is a recombinant protein-based COVID-19 vaccine that has received Emergency Use Authorization in multiple countries. Beyond vaccines, the company is leveraging its platform to develop a pipeline of oncology and autoimmune disease candidates, including biosimilars and innovative biologics.